Scribe Therapeutics (NASDAQ: SCTX) raised nearly $129 million through its initial public offering (IPO), making it one of the few successful early-stage biotech IPOs this year. The company develops CRISPR-based gene editing therapies for serious diseases and plans to use the proceeds to advance its research and clinical pipeline. Sector: Healthcare / Biotechnology Key Highlights 💰 Raised nearly $129 million through its IPO 🧬 Focused on CRISPR gene editing therapies 🚀 One of the few successful early-stage biotech IPOs 🔬 Funds will support pipeline and clinical development Why It Matters The successful IPO provides Scribe with capital to accelerate its gene editing programs while reflecting renewed investor interest in innovative biotechnology companies. https://www.thinksabio.com/reports/isr/SCTX